10y outcomes on S3 #TAVR vs SAVR in intermediate risk pts in P2A S3i is out #NYValves2025! @tnazifMD presented similar site reported ☠️ (~80% dead in 10y with mean age 80) and low reintervention (3 and 3.2%) between two groups among survivors. It gives us a good picture of the survival curves among these pts.

Hot off the press! I am pleased to announce that our new article has just been published in Frontiers in Cardiovascular Medicine frontiersin.org/journals/car… #TAVR #TAVI #interventionalcardiology #aorticvalvestenosis #comorbidity #mortality #tavi #cardiology

JUST OUT @ the 20th anniversary @PCRonline #EuroPCR25 edition of @EuroInterventio ! Our expert review on the latest in leaflet modification in #TAVR by my partner @sunnygoelmd et al eurointervention.pcronline.c… @CathElectroSurg @DoctorKini @georgedangas @KHERA_MD @ParasuramMD @manishvinayak @LucySafi @DLBHATTMD

#EuroPCR : Find out more about "How to perform optimal DK-Crush" LIVE in-vitro PCI by attending this session in the Main Arena on May 22, 16:30h! @GoranEBC @NievesGonzalo1 @M_Lesiak @twj1974 @BURZOTTA_F @gabor_gt @VisibleHeartLab @RhianEDavies1 @esbrilakis

RT @Shikha_Cardio: ACC 2025 LATE BREAKING CLINICAL TRIALS - One LINER SUMMARY 📸 AT A GLANCE ⭐️ What a phenomenal scientific meeting! Congr…

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms, and quality of life in PAD with diabetes. API-CAT: Low-dose apixaban was noninferior to full-dose for preventing VTE recurrence in cancer patients. RIVAWAR: Rivaroxaban was as effective and safe as warfarin for post-MI LV thrombus resolution at three months. FARES-II: Four-factor PCC was superior to frozen plasma for bleeding control in cardiac surgery. REVERSE-IT: Bentracimab reversed ticagrelor’s antiplatelet effects in urgent surgery or major bleeding. HOST-BR: Three-month DAPT reduced adverse events without more bleeding vs. one-month in high-bleeding-risk patients post-stent. SOUL: Oral semaglutide reduced MACE by 14% over four years with no safety concerns. ADVANCE-HTN: Lorundrostat significantly lowered systolic BP at 12 weeks in uncontrolled hypertension. DAPA-TAVI: Dapagliflozin reduced mortality and heart failure worsening post-TAVI vs. standard care.

Insightful study!

Here’s my guide to navigate the #ACC25 trials, coming this weekend and featured in many journals with a (very) high impact factor. 1. WARRIOR = Intensive medical therapy in women with ANOCA/INOCA 2. STRIDE = Semaglutide in type 2 diabetes and peripheral artery disease 3. API-CAT = Reduced-dose versus full-dose apixaban in cancer with VTE 4. FARES-II = Four-factor prothrombin complex in cardiac surgery 5. REVERSE-IT = Bentracimab in uncontrolled bleeding or requiring urgent surgery or invasive procedures 6. RIVAWAR = Rivaroxaban versus warfarin in left ventricular thrombus after MI 7. SOUL = Oral semaglutide in type 2 diabetes with ASCVD and/or CKD 8. ADVANCE-HTN = Lorundrostat in uncontrolled hypertension 9. DapaTAVI = Dapagliflozin in transcatheter heart valve treatment 10. MIGHTy-Heart = Two strategies for improving transition to home after heart failure hospitalization 11. FRESH-UP = Liberal versus restrictive fluid intake in chronic heart failure in outpatient setting 12. FAIR-HF2 = Intravenous iron in heart failure with iron deficiency 13. PROTECT-TAVI = Embolic protection in TAVI 14. ALIGN-AR = Dedicated transcatheter aortic valve in aortic regurgitation 15. Evolut Low Risk = TAVI in low-risk 16. FLAVOUR II = Angiography-derived FFR versus IVUS in PCI 17. TRILUMINATE = Tricuspid transcatheter edge-to-edge repair in tricuspid regurgitation 18. FAME 3 = FFR-guided PCI versus CABG in multivessel disease 19. RACER = Out-of-hospital cardiac arrest during long-distance running events 20. Altshock-2 = Intra-aortic balloon pump in heart failure complicated by cardiogenic shock 21. ECLIPSE = Intravascular imaging to guide PCI of severely calcified lesions in PCI 22. HOST-BR = DAPT duration based on bleeding risk

📌Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: @JACCJournals #StateOfTheArt #Review #TAVR #TAVI

Right heart catheterization @a_h_ghoneem @CBlumenthal2 @cardionerds #cardiology #medEd

See you soon at ACE Valve Academy in Liverpool!

I almost always use a figure of 8 to close 8F to 24F venous access sites. I haven’t had any major issues and I still send many patients home same day. I’ve been tempted to move to perclose but not sure the real benefit. Anyone using perclose routinely on venous closure? Tips/advice? onlinelibrary.wiley.com/doi/…

Another very practical paper in @CircIntv

Free for 50 days—review on Structural Cardiac Interventions in Patients with Heart Failure: authors.elsevier.com/a/1jdIG… @LindenfeldJoann @BurkhoffMd @TheDoctorMack @JACCJournals @ACCinTouch @escardio @HFSA @GilbertTangMD @crfheart

Nice thread by @jtsaxon about #TAVI #infolding a tricky situation in the #CathLab 😨 Check out our publication on @ccijournal summarizing #evidence about this issue 📚 onlinelibrary.wiley.com/doi/… @nicolasdumonte1 @didier_tchetche @drmaisano @DrArifK @CurioJonathan @fra_giannini1

Tips and tricks for building a good paper: what editors want ( 1/5)

what I like most from 18th EBC consensus: keep things simple and limit number of stents. knowledge of anatomy is essential so please stop starting by default with DK Crush, which should be restricted to very few anatomical scenarios @EuroInterventio eurointervention.pcronline.c…

This is one of the largest meta-analyses on the effects of exercise on cognitive performance. Here are my top 4 evidence-based protocols from it to leverage exercise to maximize cognitive performance. 1/13

I would add - DO NOT READ your slides!it is very annoying as everyone has already read everything so we do not need to hear again % of events in groups. - STOP making copy & paste of tables. the size is very small and none will read it. @PCRonline #europcr

A quick recap of new randomized trials in the fields of coronary and valvular interventions you may have missed this year at #EuroPCR if you were only watching live cases or attending practical sessions.